Coya Therapeutics, Inc.
SEC CIK 1835022 · COYA · last insider filing 2026-04-09
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Pavao Mark H | Director | filed 2026 - 2026 |
| Berman Howard | Director · Executive Chairman | filed 2022 - 2026 |
| Swaminathan Arun | Director · Chief Executive Officer | filed 2024 - 2026 |
| Ross Wilbur L JR | Director | filed 2023 - 2026 |
| Goldstein DOV A MD | Director | filed 2022 - 2026 |
| Weinand Dieter | Director | filed 2023 - 2026 |
| Villalobos Anabella | Director | filed 2022 - 2026 |
| Lee Ann | Director | filed 2022 - 2026 |
| Garren Hideki | Director | filed 2022 - 2024 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Snyder David S | Chief Financial Officer | filed 2022 - 2026 |
| Grossman Fred | Chief Medical Officer | filed 2023 - 2026 |
| Hepner Adrian | Chief Medical Officer | filed 2022 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.